Chemokines in lung transplation

肺移植中的趋化因子

• 批准号: 7099442
• 负责人: Benjamin David Medoff
• 金额: $ 12.99万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-04 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7099442
• 关键词: chemokine; chemokine receptor; chronic bronchitis; clinical research; genetic strain; human tissue; inflammation; laboratory mouse; lung ischemia /hypoxia; lung transplantation; pathologic process; pulmonary fibrosis /granuloma; transplant rejection; chemokine; chemokine receptor; chronic bronchitis; clinical research; genetic strain; human tissue; inflammation; laboratory mouse; lung ischemia /hypoxia; lung transplantation; pathologic process; pulmonary fibrosis /granuloma; transplant rejection

DESCRIPTION (provided by applicant): With the proposed Mentored Clinical Scientist Development Award the applicant will continue his investigations into basic mechanisms of lung inflammation. After two productive years in this laboratory the applicant remains firmly committed to a career in academic pulmonary medicine. The proposed research will allow the applicant to master a broad range of laboratory techniques in immunology, cell, and molecular biology. The research experience will be supplemented by a program of study of immunology and medical science. The project focuses on the development of inflammation and fibrosis following lung transplantation and the role of chemokines in these processes. After a lung is transplanted there may be several types of injury to the graft, including ischemia-reperfusion injury, acute rejection, and chronic rejection. These immune mediated injuries contribute to the development of scarring of the airways, so called bronchiolitis obliterans (BO). Over 50% of all lung transplants will develop BO after transplantation, and this remains the major cause of morbidity and mortality after lung transplantation. Neutrophils have been shown to be a prominent component of ischemia-reperfusion injury while T lymphocytes are the primary mediators of both acute and chronic rejection. The proposed project will determine which chemokines are produced after transplantation and their contribution to the development of graft injury and subsequent BO. Further experiments will manipulate chemokine or chemokine receptor expression in animal models of lung transplantation to investigate their role in the development of graft injury and BO. The applicant specifically proposes to: (1) investigate the expression of chemokines and chemokine receptors in the lung following transplantation in patients with and without acute rejection and BO; (2) investigate the role of chemokines in the development of ischemia-reperfusion injury in the airways using the murine tracheal heterotopic model of lung transplantation; (3) investigate the role of chemokines in the development of acute airway rejection and the development of BO in the murine tracheal heterotopic model of lung transplantation; (4) develop a novel murine model of airway rejection and BO.

描述（由申请人提供）： 在拟议的指导临床科学家发展奖的情况下，申请人将继续对肺部炎症的基本机制进行调查。 在该实验室工作了两年后，申请人仍然坚定地致力于学术肺医学的职业。 拟议的研究将使申请人能够掌握免疫学，细胞和分子生物学领域的广泛实验室技术。 研究经验将由免疫学和医学研究计划补充。 该项目的重点是肺移植后炎症和纤维化的发展以及趋化因子在这些过程中的作用。 移植肺后，移植物可能会造成几种损伤，包括缺血 - 灌注损伤，急性排斥和慢性排斥。 这些免疫介导的损伤有助于呼吸道疤痕的发展，所谓的细支气管炎（BO）。移植后，所有肺移植物中有50％以上将发展为BO，这仍然是肺移植后发病率和死亡率的主要原因。 嗜中性粒细胞已被证明是缺血再灌注损伤的重要组成部分，而T淋巴细胞是急性和慢性排斥反应的主要介体。 拟议的项目将确定移植后产生哪些趋化因子，以及它们对移植损伤的发展和随后的BO的贡献。 进一步的实验将在肺移植动物模型中操纵趋化因子或趋化因子受体表达，以研究其在移植损伤和BO发展中的作用。 申请人专门提出：（1）在移植和没有急性排斥和BO的患者中，研究肺中趋化因子和趋化因子受体的表达； （2）研究趋化因子在使用鼠类气管异位型肺移植模型中，趋化因子在局部缺血 - 重新灌注损伤中的作用； （3）研究趋化因子在急性气道排斥的发展中的作用和BO在鼠类气管的肺移植模型中的发展； （4）开发了一种新型的气道排斥和BO鼠模型。